21:35 , Jul 10, 2018 |  BC Innovations  |  Distillery Therapeutics

Endocrine/Metabolic

INDICATION: Diabetes Mouse studies suggest inhibiting FST could help treat insulin resistance and glucose intolerance. In a genetic mouse model of glucose intolerance and hyper insulinemia, liver-specific knockdown of FST decreased hepatic glucose production, serum insulin...
23:27 , May 1, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Non-small cell lung cancer (NSCLC) Studies in mice suggest dual inhibition of IRS1 and IRS2 could help treat KRAS-mutant NSCLC. In a mouse model of KRAS-mutant NSCLC, lung-specific dual knockout of IRS1 and IRS2 increased...
21:56 , Jan 20, 2017 |  BC Week In Review  |  Company News

TyrNovo, Kitov deal

Kitov acquired 56% of TyrNovo for $2 million in cash and $1.8 million in stock. TyrNovo’s NT219, a small molecule inhibitor of insulin receptor substrate 1 (IRS1), IRS2 and signal transducer and activator of transcription...
07:00 , Jul 28, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Insulin receptor substrate 1 (IRS1); K-Ras (KRAS); Janus kinase-1 (JAK-1); JAK-2

Cancer INDICATION: Lung cancer Patient sample, cell culture and mouse studies suggest JAK inhibitors could help treat KRAS-mutant lung cancers. In patients with KRAS-mutant lung adenocarcinoma, low primary tumor levels of IRS1 were associated with poor survival....
07:00 , Jul 24, 2014 |  BC Innovations  |  Cover Story

It is an RNA world

RNA-based molecules have redefined the universe of tractable targets by putting virtually anything that is gene encoded within reach of a disease-modifying agent. This redefinition has launched RNA as the biotech industry's third drug modality. The...
07:00 , May 19, 2014 |  BC Week In Review  |  Clinical News

Aganirsen: Phase III data

Data from 69 patients with keratitis-related progressive corneal neovascularization in the intent-to-treat (ITT) population of the double-blind, European Phase III I-CAN trial showed that twice-daily 86 µg aganirsen eye drops per eye missed the primary...
02:05 , May 13, 2014 |  BC Extra  |  Clinical News

Gene Signal publishes mixed data for aganirsen

Data published in Ophthalmology showed that twice-daily aganirsen ( GS-101) eye drops from Gene Signal International S.A. (Lausanne, Switzerland) missed the primary endpoint of improving absolute mean visual acuity value from baseline to day...
07:00 , Apr 28, 2014 |  BC Week In Review  |  Clinical News

Aganirsen: Phase IIa data

A double-blind Phase IIa trial in 12 patients with psoriasis showed that once-daily 0.86 and 1.72 mg/g topical aganirsen each met the primary endpoint of reducing psoriatic lesion size from baseline to week 6 vs....
07:00 , May 23, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Solid tumors Insulin-like growth factor-1 receptor (IGF1R; CD221); insulin receptor substrate 1 (IRS1); IRS2 SAR, cell culture...
07:00 , May 23, 2013 |  BC Innovations  |  Cover Story

IRS audit for tumors

An Israeli academic-industry partnership has discovered small molecules that interfere wi th signaling by insulin-like growth factor-1 receptor, a cancer-associated receptor tyrosine kinase. The new compounds, licensed to NovoTyr Therapeutics Ltd., could be superior to...